The 90 references in paper A. Sinopal'nikov I., А. Синопальников И. (2015) “Антихолинергические препараты в лечении хронической обструктивной болезни легких: фокус на тиотропий // Anticholinergics for therapy of chronic obstructive pulmonary disease: focus on tiotropium” / spz:neicon:pulmonology:y:2014:i:6:p:73-82

1
Atsou K., Chouaid C., Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe; systematic review. BMC Med. 2011; 9: 7–16. http:// www.biomedcentral.com/1741-7015/9/7
(check this in PDF content)
2
Buist A.S., Vollmer W.M., McBumie M.A. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int. J. Tuberc. Lung Dis.2008; 12: 703–708.
(check this in PDF content)
3
Menezes A.M., Perez-Padilla R., Hallal P.C. et al. Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int. J. Tuberc. Lung Dis. 2008; 12: 709–712.
(check this in PDF content)
4
http://www.internationalcod.org
(check this in PDF content)
5
Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation.Int. J. COPD. 2014; 12: 963–974.
(check this in PDF content)
6
Aisanov Z., Bai C., Bauerle O. et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world.Int. J. COPD.2012; 7: 1–12.
(check this in PDF content)
7
O'Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007.Can. Respir. J. 2007; 14 (Suppl. B): 5B–32B.
(check this in PDF content)
8
Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med.2011; 155: 179–191.
(check this in PDF content)
9
Broncopneumopatia cronica ostruttiva. Linee guida nazionali di riferimento er la prevenzione e la terapia. http:// www.agenas.it/images/agenas/pnlg/BPCO.pdf
(check this in PDF content)
10
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2014). http://www.goldcopd.com/uploads/users/ files/GOLD_Report_2014_Oct30.pdf
(check this in PDF content)
11
Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54. / Chuchalin A.G., Avdeev S.N., Aysanov Z.R. et al. Federal guidelines on diagnosis and management of chronic obstructive pulmonary disease. Pul'monologiya. 2014; 3: 15–54 (in Russian).
(check this in PDF content)
12
Ohar J.A., Donohue J.F. Mono- and combination theray of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin. Resir. Crit. Care Med.2010; 31: 321–333.
(check this in PDF content)
13
Johnson M., Rennard S. Alternative mechanisms for longacting beta(2)-adrenergic agonists in COPD. Chest. 2001; 120: 258–270.
(check this in PDF content)
14
Hanania N.A., Moore R.H. Anti-inflammatory activities of beta2-agonists. Cur. Drug Targets Inflam. Allergy. 2004; 3: 271–277.
(check this in PDF content)
15
Bennett W.D., Almond M.A., Zeman K.L. et al. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis.Pulm. Pharmacol. Ther. 2006; 19: 96–100.
(check this in PDF content)
16
Profita M., Giorgi R.D., Sala A. et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005; 60: 1361–1369.
(check this in PDF content)
17
CG101 chronic obstructive pulmonary disease (update): full guideline. London: National Institute for Health and Clinical Excellence; 2010. http://guidance.nice.org.uk/ CG101/Guidance
(check this in PDF content)
18
Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med.2011; 364: 1093–1103.
(check this in PDF content)
19
Chong J., Karner C., Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.Cochrane Database Syst. Rev. 2012; 9: CD009157.
(check this in PDF content)
20
Kesten S., Jara M., Wentworth C., Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006; 130: 1695–1703. Таблица 2 Клиническая эффективность АХП длительного действия у больных ХОБЛ Table 2 Clinical efficacy of long@acting anticholinergics in patients with COPD Клинический эффектАХП длительного действия ТБИсточникГликопирронийИсточникАклидинийИсточникУмеклидинийИсточник Снижение общей летальности+[55]––– Снижение летальности от сердечно!сосудистых +[55]––– причин Снижение частоты госпитализаций +[45, 48, 55, 83, 84]++[88, 89]+[87] вследствие обострений Улучшение КЖ+[85]–[90]+[86]– Снижение частоты обострений+[45, 48, 55, 83, 84]+[90]+[88, 89]
(check this in PDF content)
21
Kesten S., Celli B., Decramer M. et al. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 397–409.
(check this in PDF content)
22
Toy E.L., Beaulieu N.U., McHale J.M. et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource, and cost.Respir. Med. 2011; 105: 435–441.
(check this in PDF content)
23
Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med. J.1975; 51 (Suppl. 7): 13–20.
(check this in PDF content)
24
Jackson M. "Divine stramonium": the rise and fall of smok\u0017 ing for asthma. Med. Hist.2010; 54: 171–194.
(check this in PDF content)
25
Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.
(check this in PDF content)
26
Simons F.E. Anticholinergic drugs and the airways: "time future contained in time past".J. Allergy Clin. Immunol. 1987; 80: 239–242.
(check this in PDF content)
27
Restrepo R.D. Use of inhaled anticholinergic agents in obstructive airway disease. Respir. Care. 2007; 52: 833–851.
(check this in PDF content)
28
Barnes P.J. The pharmacological properties of tiotropium. Chest. 2000; 117 (2, Suppl.): 63S–66S.
(check this in PDF content)
29
Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive disease.Am. J. Respir. Crit. Care Med.2000; 161: 1136–1142.
(check this in PDF content)
30
Gross N.J., Co E., Skorodin M.S. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989; 96: 984–987.
(check this in PDF content)
31
Gross N.J., Skorodin M.S. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 1984; 311: 421–425.
(check this in PDF content)
32
Meurs H., Dekkers B.G., Maarsingh H. et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target.Pulm. Pharmacol. Ther.2013; 26: 145–155.
(check this in PDF content)
33
Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD.Pulm. Pharmacol. Ther.2013; 23: 257–267.
(check this in PDF content)
34
Nardini S., Camiciottoli G., Locicero S. et al. COPD: maximization of bronchodilation. Multidiscip. Respir. Med. 2014; 9: 50–60.
(check this in PDF content)
35
Sykes D.A., Dowling M.R., Leighton-Devies J. et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther.2012; 343: 520–528.
(check this in PDF content)
36
Disse B., Reichl R., Seck G. et al. Ba 679 BR, a novel longacting anticholinergic bronchodilator.Life Sci.1993; 52: 537–544.
(check this in PDF content)
37
Casarosa P., Bouyssou T., Germeyer S. et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J. Harmacol. Exp. Ther. 2009; 330: 660–668.
(check this in PDF content)
38
Haddad E.B., Patel H., Keeling J.E. et al. Pharmacological characterization of the muscarinic recetor anagonists, glycopyrrolate, in human and guinea-pig airways. Br. J. Pharmacol.1999; 127: 413–420.
(check this in PDF content)
39
Singh D., Leaker B., Tutuneu A. Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD (Abstract). Eur. Respir. J.2011; 38: 147s.
(check this in PDF content)
40
Verkindre C., Fucuchi Y., Flemale A. et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir. Med. 2010; 104: 1482–1489.
(check this in PDF content)
41
Breekveldt-Postma N.S., Koerselman J., Erkens J.A. et al. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir. Med. 2007; 101: 1398–1405.
(check this in PDF content)
42
Cramer J.A., Bradley-Kennedy C., Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can. Respir. J.2007; 14: 25–29.
(check this in PDF content)
43
Beeh K.M., Beier J. The short, the long, and the "ultra\u0017 long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.Adv. Ther. 2010; 27: 150–159.
(check this in PDF content)
44
Taube C., Lehnigk B., Paasch K. et al. Factor analysis of changes in dyspnae and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2000; 162: 216–220.
(check this in PDF content)
45
Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.Eur. Respir. J.2002; 19: 217–224.
(check this in PDF content)
46
O'Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilator response to exercise in chronic obstructive pulmonary disease.Eur. Respir. J. 2004; 24: 86–94.
(check this in PDF content)
47
Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium.Pulm. Pharmacol. Ther. 2005; 18: 75–81.
(check this in PDF content)
48
Vincken W., van Noord J.A., Greefhorst A.P. et al. Dutch / Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.Eur. Respir. J.2002; 19: 209–216.
(check this in PDF content)
49
Gauhar U., Dransfield M., Cooper J.A. Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting. Int. J. Chron. Obstruct. Pulm. Dis.2009; 4: 391–395.
(check this in PDF content)
50
Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med.2005; 143: 317–326.
(check this in PDF content)
51
Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122: 47–55.
(check this in PDF content)
52
Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003; 58: 399–404.
(check this in PDF content)
53
Briggs D.D. Jr, Covelli H., Lapidus R. et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm. Pharmacol. Ther. 2005; 18: 397–404.
(check this in PDF content)
54
Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008; 133: 1079–1087.
(check this in PDF content)
55
Tashkin D.P., Celli B., Senn S. et al. for UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.N. Engl. J. Med.2008; 359: 1543–1554.
(check this in PDF content)
56
Anzueto A., Miravitlles M. Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther. Adv. Respir. Dis. 2009; 3: 103–111.
(check this in PDF content)
57
Celli B., Decramer M., Kesten S. et al. Mortality in the 4-year of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med.2009; 15: 948–955.
(check this in PDF content)
58
Gershon A.S., Wang L., To T. et al. Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive pulmonary disease. COPD. 2008; 4: 229–234.
(check this in PDF content)
59
Burgel P.-R., Paillasseur J.-L., Dusser D. et al. Tiotropium might improve survival in subjects with COPD at high risk of mortality.Respir. Res.2014; 15 (64): 1–10.
(check this in PDF content)
60
Cazzola M., Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23: 257–267.
(check this in PDF content)
61
COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. A 85-day multicenter trial. Chest. 1994; 105: 1411–1419.
(check this in PDF content)
62
Nord J.A., de Munck D.R., Bantje T.A. et al. Longterm treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J.2000; 15: 878–885.
(check this in PDF content)
63
Cazzola M., Tashkin D.P. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD. 2009; 6: 404–415.
(check this in PDF content)
64
Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J.2012; 21: 101–108.
(check this in PDF content)
65
Mahler D.A., D'Urzo A., Bateman E.D. et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparison. Thorax. 2012; 67: 781–788.
(check this in PDF content)
66
Matera M.G., Rogliani P., Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 2014; 15: 961–977.
(check this in PDF content)
67
Aalbers R., Maleki-Yazdi M.R., Hamilton A. et al. Dosefinding study for tiotropium and olodaterol when administration in combination via Resimat inhaler in patients with COPD [abstract]. Eur. Respir. J.2012; 40: 525–526s.
(check this in PDF content)
68
Johnson M. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc.2005; 2: 320–325; discussion 340–341.
(check this in PDF content)
69
Singh D., Brooks J., Hagan G. et al. Superiority of "triple" therapy with salmeterol / fluticasone propionate and tiotropium bromide versus in individual components in moderate to severe COPD. Thorax. 2008; 63: 592–598.
(check this in PDF content)
70
Perng D.W., Wu C.C., Su K.C. et al. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology. 2006; 11: 598–602.
(check this in PDF content)
71
Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med.2007; 146: 545–555.
(check this in PDF content)
72
Lee T.A., Wilke C., Joo M. et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.Arch. Intern. Med. 2009; 169: 1403–1410.
(check this in PDF content)
73
Rodrigo G.J., Plaza V., Casto-Rodriguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Ulm. Pharmacol. Ther. 2012; 25: 40–47.
(check this in PDF content)
74
Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomized clinical trials. Lancet. 2009; 374: 695–703.
(check this in PDF content)
75
Sun S.X., Marynchenko M., Banerjee R. et al. Cost-effectiveness analysis of roflumilast / tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.J. Med. Econ.2011; 14: 805–815.
(check this in PDF content)
76
Michele T.M., Pinheiro S., Iyasu S. The safety of tiotropium – the FDA's conclusions. N. Engl. J. Med. 2010; 363: 1097–1099.
(check this in PDF content)
77
Singh S., Loke Y.K., Enright P.L. et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and metaanalysis of randomized controlled trials. Br. Med. J.2011; 342: d3215.1–9.
(check this in PDF content)
78
Verhamme K., Afonso A., Romio S. et al. Use of tiotropium Respimat SMI versus tiotropium HandiHaler and mortality in patients with COPD. Eur. Respir. J. 2013; 42: 606–615.
(check this in PDF content)
79
Jenkins C.R., Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013; 68: 5–7.
(check this in PDF content)
80
Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491–1501.
(check this in PDF content)
81
Barnes N.C., Jones P.W., Davis K.J. Safety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm? Thorax. 2014; 69: 598–599.
(check this in PDF content)
82
Yohanes A.M., Connoly M., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives.Intern. J. COPD.2013; 8: 117–125.
(check this in PDF content)
83
Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27: 547–555.
(check this in PDF content)
84
Powrie D.J., Wilkinson T.M., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Resir. J.2007; 30: 472–478.
(check this in PDF content)
85
Tonnel A.B., Perez T., Grosbois J.M. et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int. J. COPD. 2008; 3: 301–310.
(check this in PDF content)
86
Reid D.J., Carlson A.A. Clinical use of aclidinium in patients with COPD.Intern. J. COPD.2014; 9: 369–379.
(check this in PDF content)
87
Donohue J.F., Niewoehner D., Brooks J. et al. Safety and tolerability of once-daily umeclidinium / vilanterol 125 / 25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir. Res. 2014; 15: 78–86.
(check this in PDF content)
88
Kerwin E.M., D'Urzo A.D., Gelb A.F. et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9: 90–101.
(check this in PDF content)
89
Jones P.W., Singh D., Bateman E.D. et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J.2012; 40: 830–836.
(check this in PDF content)
90
D'Urzo A.D., Ferguson G.T., van Noord J.A. et al. Efficacy and safety of once-daily NVA237 in patients with moderateto-severe COPD: the GLOW1 trial. Respir. Res.2011; 12: 156–163. Поступила 18.12.14
(check this in PDF content)